Researchers at the National Institutes of Health (NIH) have shown that inhibition of myeloid-derived suppressor cell (MDSC) trafficking into mouse solid tumors by SX-682 enhanced both PD-1 immune checkpoint blockade (ICB) and T cell receptor (TCR) engineered T cell immunotherapy, leading to significant tumor growth inhibition or eradication. The research, published last week in JCI Insight, suggests a promising new approach for treating patients with solid tumors using a combination of SX-682 and multiple forms of immunotherapy including ICB and adoptive cell transfer with engineered T cells. The results arose from a Cooperative Research and Development Agreement (CRADA) between Syntrix and NIH.
Read more: https://prn.to/2ULoYry